Back to search results

Safety and Tolerability of CVGBM in Adults With Newly Diagnosed MGMT-Unmethylated Glioblastoma or Astrocytoma

Abroad (travel likely)CompletedPHASE1

Conditions

Glioblastoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Universitair Ziekenhuis Brussel - PPDS, Brussels, Belgium

  • CHU de Liège, Liège, Belgium

  • Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • University Clinic Heidelberg, Heidelberg, Baden-Wurttemberg, Germany

  • Universitätsmedizin Mannheim, Mannheim, Baden-Wurttemberg, Germany

  • Universitätsklinikum Tübingen, Tübingen, Baden-Wurttemberg, Germany

  • University Clinic Regensburg, Regensburg, Bavaria, Germany

  • Universitätsklinikum Frankfurt, Frankfurt am Main, Hesse, Germany

  • Universitätsklinikum Bonn, Bonn, North Rhine-Westphalia, Germany

  • University Hospital Essen, Essen, North Rhine-Westphalia, Germany

  • Universitatsklinikum Leipzig, Leipzig, Saxony, Germany

  • Neurosurgical Clinic at the LMU Munich, München, Germany

  • Erasmusmc Cancer institute, Rotterdam, South Holland, Netherlands

Study leads

  • Clinical Trial Information

    Study Director

    CureVac SE

View source on ClinicalTrials.gov(opens in a new tab)

No study contact email or phone is listed for this trial.